Premium
Survival analysis in families affected by hereditary non‐polyposis colorectal cancer
Author(s) -
Percesepe Antonio,
Benatti Piero,
Roncucci Luca,
Sassatelli Romano,
Fante Rossella,
Ganazzi Dorval,
Bellacosa Alfonso,
Genuardi Maurizio,
Neri Giovanni,
Viel Alessandra,
Ponz de Leon Maurizio
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970502)71:3<373::aid-ijc12>3.0.co;2-h
Subject(s) - colorectal cancer , medicine , proportional hazards model , cancer , oncology , stage (stratigraphy) , population , survival analysis , cancer registry , survival rate , biology , paleontology , environmental health
Previous survival studies suggested a better prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) patients compared with the sporadic counterpart. In the present study we evaluated the clinical outcome of HNPCC patients with respect to that of patients with colorectal cancer recorded in a population‐based cancer registry. We assessed survival of 85 colorectal cancer patients from 24 unrelated families defined as having HNPCC according to the criteria of the International Collaborative Group, for whom adequate information on subject‐ and tumor‐related parameters and a 5‐year follow‐up (cancer diagnosis from 1980‐1989) were available. Three hundred and seventy‐seven colorectal cancer patients, registered from 1984‐1986, with a 5‐year follow‐up, were used for comparison. Colorectal cancer‐specific 5‐year survival rates were 55.2% and 42.5% for HNPCC and non‐HNPCC, respectively. Using Cox regression analysis, tumor staging and location were independently associated with survival, whereas HNPCC diagnosis was not. Stage II HNPCC cases exhibited a better prognosis than non‐HNPCC patients. By Cox regression analysis, none of the variables were significantly related to survival. Both overall and stage II HNPCC cases showed a survival advantage in comparison with non‐HNPCC patients. However, the difference disappeared when clinical and pathological variables were controlled for with a Cox regression analysis. Int. J. Cancer 71:373‐376, 1997. © 1997 Wiley‐Liss Inc.